R&D of dietary supplements, pharmaceutical products and medical devices

AAT Advanced Analytical Technologies Fiorenzuola D’arda (Piacenza)

AAT was born as a spin-off of Cattolica University of Piacenza in 2005, with the goal of promoting the scientific approach to innovation in the probiotics sector.

Through the innovative use of microbes, it develops solutions and B2B services for food, pharmaceutical and cosmetics companies. This is the reason why Coree has chosen AAT to establish a fruitful collaboration: for the competence, the reliability and the elasticity in proposing the best paths to figure out and to support new probiotic strains which can make the difference on the market.

The collaboration with Coree Italia has started in 2016 and is based on the conduction of analytical and R&D services through in-vitro models and pre-clinical studies during various stages of the development of new probiotics-based products. AAT is a fast-growing reality, among the most skilled in this field not only at a national but also international level.

Fondazione Policlinico Universitario Agostino Gemelli – Università Cattolica Del Sacro Cuore (Roma)

The research of new fields in which to exploit the infinite potential of probiotic bacterias, characterized and studied to support the well-being of the individual in various diversified situations, brought Coree Italia to consolidate a close collaboration with the Department of Medical and Surgical Sciences Operating Unit of Internal Medicine and Gastroenterology of Gemelli Hospital, especially on long-term projects about the role of the gut microbiota and its metabolites in diabetes and obesity.

What characterizes the microbiota of individuals with metabolic diseases that are becoming increasingly prevalent worldwide, creating an overload for healthcare facilities as well as a high health risk for the individuals themselves? How can we support the normal therapies used in the medical field to address these issues? Coree Italy wanted to be at the forefront in seeking an answer to these questions, with a multi-year observational study, identifying useful biomarkers to build a multi-omics database that would allow the collection of information on the characteristics of these metabolic diseases to hopefully have a predictive function on the incidence and severity of these diseases.

Fondazione Ca’ Granda – Policlinico Ospedale Pediatrico (Milano)

Coree Italia approached Policlinico Ca’ Granda on the basis of the historical solidity of this institution and wanting to have, even for its pediatric application products, the support of a nationwide excellence.
Coree vocation about R&D brought to the development of products aimed at supporting the general well-being of different consumers’ targets. The first and most important field of collaboration has been the pedriatical one, which is characterized by the fine-tuning of products that keep in consideration the clinical experience among specialists, developed in cure-centers and their precious feedbacks related to daily-life in contact with mothers and children.

This collaboration has then become a point of reference for Coree, bringing to planning and implementatio of strategic clinical studies to check and explore new and challenging issues in depth.

Istituto Di Ricerche Farmacologiche Mario Negri (Milano)

The Mario Negri Institute is a non-profit organization founded in 1961 and operating in the biomedical field, to the service of public healthcare.

Focusing on the issues of every age and wanting to provide a different support, possibly additional, to the pharmaceutical one to every stage of life, Coree Italia has found in Mario Negri Institute an ideal partner for the conception and management of different projects, such as the start of a preclinical phase for a proprietary probiotic strain capable of enhancing immune response. This strain is currently under a European patent application process.

This pre-clinical phase may be followed by clinical development of the strain designed, in particular, to be combined as a “booster” for mucosal vaccination, a form of vaccine administration such as the one by nasal sprays or oral drops that offers many advantages: lower cost, greater accessibility to vaccination, needle-free administration, and greater capacity for mass vaccination in emergency situations, such as during pandemics.

Hanmi Pharmacuetical

Coree Italia has always had close partnerships with Hanmi Pharmaceutical group, a Korean pharmaceutical company, leader in Asia, whose business is focused on drugs dedicated to specific therapeutic areas, such as obesity/metabolic diseases, oncology and rare diseases.

Thanks to this collaboration, Coree Italia is therefore supporting Hanmi Pharmaceutical with innovative ideas and scientifically strong results to support the pharmaceutical group’s Research.

Coree Group

Coree Italia is the youngest subsidiary of this group and has also introduced in Europe the Ofmom (Mother Child and beyond) brand, which has been present for a long time in China and Korea, where Coree Group is well established. The Ofmom brand includes various products that are highly appreciated by mothers because they focus on providing quality nutritional supplies with a strong scientific backgorund such as follow-on milks, food supplements and probiotics for infants, babies of all ages and their mothers (e.g. Formulamate and follow-on milks).

In Italy, Ofmom’s launch took place with the full development of the SynterAct Bimbi ® formula, entirely made in Italy and also created thanks to the local network of scientific collaborations. The product, launched in 2020, is characterized by the innovative technology with which the mixture of probiotics at its base (SynterAct Formula) was obtained and which earned it the registration of a European patent.

Dx&Vx Limited

In recent years, Coree Italia has entered into a close partnership with the Dx&Vx Limited group, based in Seoul, Korea. Dx&Vx Ltd. focuses on the development of advanced diagnostic solutions for medicine of precision and, in parallel, the development of innovative tools for the prevention of infectious diseases. The company was established to move in a cutting-edge scientific field: in fact, it deals with genome analysis and molecular diagnostics.

Fusing both companies’ vocation for “scientifically supported innovation,” the collaboration between Coree Italia and Dx&Vx Ltd. focused on the development of food supplements with probiotics designed on specific needs of target consumers. The launch in Italy of the Dx&Vx line, food supplements for adults, is the first result of this joint work, in which the product concept and line graphics were entirely developed in Italy.